Exeliom Biosciences
Exeliom Biosciences
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients | Bacterial Infections and Mycoses, Clostridium difficile Infections, Clostridium infectious disease, Disease Attributes, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Recurrent Infection, Reinfection, bacterial infectious disease, gram-positive bacterial infections | Recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT06306014 | |
| EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-09-25 | NCT06448572 |